Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Despite high organ toxicity, CD19 CART T cell therapy shows low nonrelapse mortality

Publish date:: July 22, 2020

Key clinical point: The 1-year nonrelapse mortality and overall survival were 1.7% and 69%, respectively.

Major finding: A total of 539 grade 2 or greater and 280 grade 3 or greater toxicities were observed.

Study details: Toxicities in organ-based groups assessed in 60 patients with DLBCL treated with CD19 CAR T cells.

Disclosures: The authors reported various relationships with multiple pharmaceutical and biotechnology companies.

Citation:

Wudhikarn K et al. Blood Advances. 2020; 4[13]:3024-33.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,